Barclays analyst Eliana Merle lowered the firm’s price target on Gossamer Bio (GOSS) to 28c from 30c and keeps an Underweight rating on the shares. The company’s exchange offer for its 2027 notes reduced debt and extends maturity, which is positive, but is meaningfully equity dilutive, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Midday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp
- Morning Movers: LiveRamp jumps following pact to be acquired by Publicis
- Gossamer Bio Restructures Debt and Advances Seralutinib Program
- Gossamer Bio launches exchange offer, consent solicitation
- Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year